INSILICO (03696) has reached collaboration agreements with CMS worth tens of millions of Hong Kong dollars in the research and development of multiple drugs in the central nervous system and autoimmune disease fields.

INSILICO (03696) announced that the group has reached a strategic cooperation with CMS in drug research and development. Through this collaboration, both parties will achieve a series of AI-powered innovative drug research and development cooperation in the central nervous system and autoimmune disease fields. According to the agreement of this collaboration, both parties will combine INSILICO's validated AI platform and AI-powered innovative drug R&D capabilities with CMS's experienced R&D team and deep understanding of the disease field to jointly advance collaboration on at least 2 R&D projects. At the same time, INSILICO is expected to receive up to tens of millions of Hong Kong dollars in R&D support for each project.